Keymed Biosciences Co.ltd

This study tests a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The goal is to see if the drug is safe and helps clear the skin. Participants receive the drug and are monitored for side effects and improvements in eczema severity.